A Study of AND019 in Women With ER Positive HER2 Negative Advanced or Metastatic Breast Cancer

Recruiting

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

Sarah Cannon Research Institute, Nashville, Tennessee